FDA To Review Whether To Allow More Access To Certain Peptides
April 17, 2026
By HealthDay Staff HealthDay ReporterFRIDAY, April 17, 2026 (HealthDay News) — The U.S. Food and Drug Administration (FDA) will soon review whether...
The Food and Drug Administration is set to reconsider its restrictions on a number of injectable peptide therapies popular in wellness and anti-aging circles. The agency announced it will convene a panel of outside experts in July to review whether to allow licensed compounding pharmacies to produce more than half a dozen of these substances. This move signals a potential policy shift from the agency's previous position, which had cited significant safety concerns and a lack of clinical data for limiting their use. The upcoming meeting will specifically assess seven peptides, with a review of five additional substances planned to occur before the end of February 2027.
Peptides are short chains of amino acids that serve as building blocks for proteins and play various roles in the body. While more than 80 FDA-approved drugs are peptide-based, including well-known medications like insulin and the new class of GLP-1 weight-loss drugs, the substances currently under review occupy a regulatory gray area. Many of these unapproved peptides have gained popularity through online influencers and wellness clinics, promoted for benefits such as muscle growth, injury healing, and reduced inflammation. However, public health experts and scientists have expressed caution, highlighting that most of these compounds have not undergone the rigorous, large-scale clinical trials required to establish their safety and effectiveness.
The FDA's decision to revisit the issue comes after the agency, in 2023, added nearly 20 peptides to a list of substances that should not be produced by compounding pharmacies due to potential safety risks, including issues of toxicity and impurity. That move triggered pushback from wellness entrepreneurs, compounding pharmacies, and their advocates. Proponents for easing the restrictions, including Health and Human Services Secretary Robert F. Kennedy Jr., argue that the 2023 decision inadvertently fueled a dangerous black market for the substances. They contend that allowing regulated access through legitimate pharmacies would provide a safer alternative to the unregulated products currently being sold.
At the center of this debate are compounding pharmacies, which create customized medications for patients with specific needs not met by commercially available drugs. These pharmacies have faced increasing demand from both patients and prescribers for peptide therapies they are legally barred from producing. Trade groups representing these pharmacies argue that a regulated pathway for compounding would address this demand while ensuring higher quality control than the illicit market currently provides. However, they also caution that any regulatory change must be managed carefully to ensure a stable supply of pharmaceutical-grade ingredients is available to avoid confusion and supply chain disruptions.
The immediate next step is the FDA's Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026. The committee will review the first set of seven peptides, including the popular BPC-157, and provide a recommendation on whether they should be added to the list of substances that can be used for compounding. The FDA's final decision, which will follow the panel's review, could reshape the regulatory landscape for these therapies. It aims to balance the demand for access from patients and the wellness industry against the safety concerns raised by the lack of comprehensive scientific evidence.
Source: usnews